Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Averica Discovery Systems
Averica Discovery Systems
Activities:
Research & Development
X
LinkedIn
Trending Articles
Merck's MilliporeSigma cuts the ribbon on €290m US biosafety and analytical facility
The site will host biosafety testing, analytical development and cell banking manufacturing services
Johnson & Johnson completes V-Wave acquisition to support patients with heart failure
The strategic acquisition will bolster the pharma giant's MedTech offerings for patients with cardiovascular disease
Calluna Pharma appoints Mark Gaffney as CEO and Mark Altmeyer as Chair of the Board
The two will work to advance the company's global presence, while developing its lead programme
ABITEC Corporation bolsters its high-purity lipid offerings for LNP therapeutics
The company can provide cGMP-grade lipids from a mg to a kg scale, assisting the production of advanced LNP therapeutics, including vaccines
Roche's breast cancer combination therapy Itovebi bags FDA approval
Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients
Upcoming event
ISCC
15-18 October 2024 | Conference | Milan, Italy
See all
Related Content
Ingredients
Averica expands pharmaceutical impurities services
Averica Discovery Services has expanded its service to include services such as nitrosamine and PFAS testing
Research & Development
Canadian-based Neopharm Labs completes acquisition of Boston-based Averica Discovery Services
The combined expertise creates a key player in the North American analytical market
Research & Development
Averica Discovery appoints Cynthia Berger as Vice President of Operations
Will contribute broadly to the firm's growth and development
Regulatory
Averica now able to handle Schedule I controlled substances
And expand the types of research that the company can support
Subscribe now